SMTL ID : 5ouk.1

Crystal structure of human AKR1B1 complexed with NADP+ and compound 41

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 0.96 Å

Oligo State

monomer

Ligands

1 x NAP: NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)

NAP.1: 33 residues within 4Å: Chain A: G.19, T.20, W.21, K.22, D.44, Y.49, K.78, H.111, W.112, S.160, N.161, Q.184, Y.210, S.211, P.212, L.213, G.214, S.215, P.216, D.217, L.229, A.246, I.261, P.262, K.263, S.264, V.265, T.266, R.269, E.272, N.273, C.299 Ligands: AVT.2 33 PLIP interactions: 33 interactions with chain A Hydrophobic interactions: A:W.21, A:Y.210, A:Y.210, A:Y.210 Hydrogen bonds: A:T.20, A:W.21, A:D.44, A:S.160, A:N.161, A:Q.184, A:S.211, A:L.213, A:S.215, A:S.215, A:D.217, A:D.217, A:K.263, A:K.263, A:V.265, A:T.266, A:E.272, A:N.273 Water bridges: A:D.217, A:D.217, A:T.266, A:R.269, A:R.269, A:R.269, A:R.269 Salt bridges: A:K.22, A:K.263, A:R.269 pi-Cation interactions: A:R.269

1 x AVT: 2-[9-fluoranyl-5-(4-methoxyphenyl)-3-methyl-1-oxidanylidene-pyrimido[4,5-c]quinolin-2-yl]ethanoic acid(Non-covalent)

AVT.2: 15 residues within 4Å: Chain A: W.21, V.48, Y.49, Q.50, W.80, H.111, W.112, F.122, F.123, W.220, C.299, L.301, L.302, S.303 Ligands: NAP.1 14 PLIP interactions: 14 interactions with chain A Hydrophobic interactions: A:W.21, A:V.48, A:F.123, A:F.123, A:F.123, A:W.220 Hydrogen bonds: A:Y.49, A:L.302, A:S.303 Water bridges: A:W.112, A:S.303 Salt bridges: A:H.111 pi-Stacking: A:W.220 Halogen bonds: A:Q.50

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Crespo, I. et al., Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase. Eur J Med Chem (2018)

Release Date

2018-05-09

Peptides

Aldose reductase: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Aldose reductase

Related Entries With Identical Sequence